{"id":295757,"date":"2019-10-03T16:05:40","date_gmt":"2019-10-03T23:05:40","guid":{"rendered":"https:\/\/nai500.com\/?p=295757"},"modified":"2019-10-03T16:05:40","modified_gmt":"2019-10-03T23:05:40","slug":"%e9%bb%98%e5%85%8b-keytruda-%e7%8d%b2%e6%89%b9%e5%9c%a8%e8%8f%af%e4%bd%9c%e7%82%ba%e8%82%ba%e7%99%8c%e5%96%ae%e4%b8%80%e7%99%82%e6%b3%95","status":"publish","type":"post","link":"https:\/\/nai500.com\/zh-hant\/blog\/2019\/10\/%e9%bb%98%e5%85%8b-keytruda-%e7%8d%b2%e6%89%b9%e5%9c%a8%e8%8f%af%e4%bd%9c%e7%82%ba%e8%82%ba%e7%99%8c%e5%96%ae%e4%b8%80%e7%99%82%e6%b3%95\/","title":{"rendered":"\u9ed8\u514bKeytruda\u7372\u6279\u5728\u83ef\u4f5c\u70ba\u80ba\u764c\u55ae\u4e00\u7642\u6cd5"},"content":{"rendered":"<p>\u9ed8\u514b\u5ba3\u4f48\uff0c\u9ed8\u514b\u7684\u6297PD-1\u514d\u75ab\u7642\u6cd5Keytruda\u5df2\u5728\u4e2d\u570b\u7372\u5f97\u6279\u51c6\uff0c\u6210\u70ba\u7121\u9700\u5316\u7642\u5373\u53ef\u6cbb\u7642\u665a\u671f\u6216\u8f49\u79fb\u6027\u975e\u5c0f\u7d30\u80de\u80ba\u764c\uff08NSCLC\uff09\u7684\u4e00\u7dda\u55ae\u4e00\u7642\u6cd5\u3002\u6b64\u524d\uff0c\u4e2d\u570b\u570b\u5bb6\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40\u6279\u51c6Keytruda\u4f5c\u70ba\u806f\u5408\u5316\u7642\u6cbb\u7642NSCLC\u7684\u4e00\u7dda\u6cbb\u7642\u85e5\u7269\uff0c\u4e26\u65bc2018\u5e74\u5728\u4e2d\u570b\u88ab\u6279\u51c6\u4f5c\u70ba\u8f49\u79fb\u6027\u9aa8\u9ad3\u7624\u7684\u4e8c\u7dda\u6cbb\u7642\u85e5\u7269\u3002\u9ed8\u514b\u8868\u793a\uff0c\u5728\u4e00\u9805\u5168\u7403NSCLC\u8a66\u9a57\u7684\u4e2d\u570b\u64f4\u5c55\u8a66\u9a57\u4e2d\uff0c\u8207\u5316\u7642\u76f8\u6bd4\uff0c\u9ed8\u514b\u7684Keytruda\u5728\u7e3d\u9ad4\u5b58\u6d3b\u7387\u65b9\u9762\u5177\u6709\u7d71\u8a08\u5b78\u4e0a\u7684\u986f\u8457\u6539\u5584\u3002<\/p>\n<p>\u82f1\u6587\u4f86\u6e90\uff1aChina Biotoday<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck\/MSD announced China approval of Keytruda, the company&#8217;s anti-PD-1 immunotherapy, as a first-line monotherapy to treat advanced or metastatic non-small cell lung cancer without chemotherapy. Previously, China&#8217;s NMPA approved Keytruda as a first line NSCLC treatment together with chemotherapy, and in 2018, it was approved in China as a second-line treatment for metastatic myeloma. <\/p>\n","protected":false},"author":9,"featured_media":281875,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[426],"tags":[927,563],"class_list":["post-295757","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-news-zh-hant","tag-927","tag--zh-hant","sectors-life-science-zh-hant","locations-china-zh-hant","locations-us-zh-hant","exchange-nyse-zh-hant"],"acf":[],"_links":{"self":[{"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/posts\/295757","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/comments?post=295757"}],"version-history":[{"count":0,"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/posts\/295757\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/media\/281875"}],"wp:attachment":[{"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/media?parent=295757"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/categories?post=295757"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/tags?post=295757"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}